Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trial (2019)
- Authors:
- Autor USP: NICOLAU, JOSÉ CARLOS - FM
- Unidade: FM
- DOI: 10.1093/eurheartj/ehz299
- Subjects: INFARTO DO MIOCÁRDIO; INSUFICIÊNCIA CARDÍACA; ENZIMAS PROTEOLÍTICAS; ESTATINAS
- Agências de fomento:
- Language: Inglês
- Imprenta:
- Source:
- Título do periódico: European heart journal
- ISSN: 0195-668X
- Volume/Número/Paginação/Ano: v. 40, n. 33, p. 2801-2809, 2019
- Este periódico é de assinatura
- Este artigo é de acesso aberto
- URL de acesso aberto
- Cor do Acesso Aberto: hybrid
- Licença: cc-by-nc
-
ABNT
WHITE, Harvey D et al. Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trial. European heart journal, v. 40, n. 33, p. 2801-2809, 2019Tradução . . Disponível em: https://doi.org/10.1093/eurheartj/ehz299. Acesso em: 16 maio 2024. -
APA
White, H. D., Steg, P. G., Szarek, M., Bhatt, D. L., Bittner, V. A., Diaz, R., et al. (2019). Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trial. European heart journal, 40( 33), 2801-2809. doi:10.1093/eurheartj/ehz299 -
NLM
White HD, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, Edelberg JM, Erglis A, Goodman SG, Nicolau JC. Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trial [Internet]. European heart journal. 2019 ; 40( 33): 2801-2809.[citado 2024 maio 16 ] Available from: https://doi.org/10.1093/eurheartj/ehz299 -
Vancouver
White HD, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, Edelberg JM, Erglis A, Goodman SG, Nicolau JC. Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trial [Internet]. European heart journal. 2019 ; 40( 33): 2801-2809.[citado 2024 maio 16 ] Available from: https://doi.org/10.1093/eurheartj/ehz299 - Ticagrelor versus clopidogrel in patients with STEMI treated with fibrinolysis TREAT trial
- Ticagrelor vs Clopidogrel After Fibrinolytic Therapy in Patients With ST-Elevation Myocardial Infarction: A Randomized Clinical Trial (vol 3, pg 391, 2018)
- Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction Results From the DAPA-HF Trial
- Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to Age Insights From DAPA-HF
- Effect of alirocumab on mortality after acute coronary syndromes an analysis of the ODYSSEY OUTCOMES randomized clinical trial
- Predicting risk of cardiovascular events 1 to 3 years post-myocardial infarction using a global registry
- Long-term ticagrelor for secondary prevention in patients with prior myocardial infarction and no history of coronary stenting: insights from PEGASUS-TIMI 54
- Two-year outcomes among stable high-risk patients following acute MI. Insights from a global registry in 25 countries
- Anti-Thrombotic Therapy to Ameliorate Complications of COVID-19 (ATTACC): Study design and methodology for an international, adaptive Bayesian randomized controlled trial
- Rationale and design of the long-Term rIsk, clinical manaGement, and healthcare Resource utilization of stable coronary artery dISease in post-myocardial infarction patients (TIGRIS) study
Informações sobre o DOI: 10.1093/eurheartj/ehz299 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
